ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the filing of a DEF 14A form with the SEC, scheduling its 2024 Annual Meeting of Stockholders for October 29, 2024. The virtual meeting will invite stockholders to elect a Class II director nominee, ratify the selection of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2024, approve an amendment to increase the number of shares for the 2022 Omnibus Equity Incentive Plan, and approve the issuance of shares upon the exercise of certain warrants. The meeting will also address other business as necessary. The record date for the Annual Meeting is September 4, 2024, with only stockholders of record or their proxies eligible to vote. The company emphasizes the importance of stockholders submitting a proxy to vote their shares prior to the meeting.

ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the filing of a DEF 14A form with the SEC, scheduling its 2024 Annual Meeting of Stockholders for October 29, 2024. The virtual meeting will invite stockholders to elect a Class II director nominee, ratify the selection of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2024, approve an amendment to increase the number of shares for the 2022 Omnibus Equity Incentive Plan, and approve the issuance of shares upon the exercise of certain warrants. The meeting will also address other business as necessary. The record date for the Annual Meeting is September 4, 2024, with only stockholders of record or their proxies eligible to vote. The company emphasizes the importance of stockholders submitting a proxy to vote their shares prior to the meeting.